The New York Stock Exchange ended the session with Pfizer rising 0.25% to $36.61 on Tuesday while the New York Stock Exchange rose 1.79% to $14,249.50.
Pfizer yesterday’s close was $36.52, under its 52-week high of $39.84.
Pfizer’s sales growth is a negative 9.7% for the current quarter and a decline by 8.8% for the next. The company’s growth estimates for the present quarter and the next is a negative 12.7% and a negative 17.5%, respectively.
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer’s stock is valued at $36.61 at 19:57 EST, under its 52-week high of $39.84 and way higher than its 52-week low of $26.45.
Pfizer’s worth is higher than its 50-day moving average of $35.36 and higher than its 200-day moving average of $34.77.
U.k. may give go-ahead to Pfizer vaccine before u.s.: telegraph. According to Bloomberg Quint on Sun Nov 22, “U.K”
According to Bloomberg Quint on Mon Nov 23, “U.K”